- Preparation process of N-(2-acetamido)-2-iminodiacetic acid
-
The invention discloses a preparation process of N-(2-acetamido)-2-iminodiacetic acid. The preparation process comprises the following steps: subjecting a reactant 1 with a structure as shown in a formula as described in the specification to reacting with a nitrogen-containing compound, and subjecting the obtained intermediate product to reacting with an amination reagent to obtain N-(2-acetamido)-2-iminodiacetic acid. In the formula, Y, Y1, Y2 and Y3 are respectively one selected from the group consisting of OH, OM, halogen, OR and SR; and Z is one selected from the group consisting of halogen, OH and SH. According to the invention, low-price starting raw materials are used, so cost can be greatly reduced; reaction conditions are mild, a subsequent purification process is simple, and theyield of N-(2-acetamido)-2-iminodiacetic acid is high; and the whole process disclosed by the invention is relatively simple to operate and easy to control, is beneficial for scale-up production, shortens the reaction production period, and is also beneficial to academic research and the like of N-(2-acetamido)-2-iminodiacetic acid.
- -
-
Paragraph 0039-0040; 0044-0054; 0058-0068; 0072-0082
(2020/11/23)
-
- Isolation of nucleic acids
-
A method for extracting nucleic acids from a biological material such as blood comprises contacting the mixture with a material at a pH such that the material is positively charged and will bind negatively charged nucleic acids and then eluting the nucleic acids at a pH when the said materials possess a neutral or negative charge to release the nucleic acids. The nucleic acids can be removed under mildly alkaline conditions to the maintain integrity of the nucleic acids and to allow retrieval of the nucleic acids in reagents that are immediately compatible with either storage or analytical testing.
- -
-
-
- Isolation of nucleic acids
-
A method for extracting nucleic acids from a biological material such as blood comprises contacting the mixture with a material at a pH such that the material is positively charged and will bind negatively charged nucleic acids and then eluting the nucleic acids at a pH when the said materials possess a neutral or negative charge to release the nucleic acids. The nucleic acids can be removed under mildly alkaline conditions to the maintain integrity of the nucleic acids and to allow retrieval of the nucleic acids in reagents that are immediately compatible with either storage or analytical testing.
- -
-
-
- Syntheses of (N → B)phenyl[N-alkylaminodiacetate-O,O′,N]boranes
-
The syntheses of (N → B)phenyl[N-alkylaminodiacetate-O,O′,N]boranes (2 to 6) and their corresponding N-alkylaminodiacetic acids (7 to 10) are reported. All compounds (except 6) were characterized by 1H, 11B (for boron heterocycles), 13C NMR, infrared spectroscopy and mass spectrometry. The 1H NMR spectrum of compound 3 shows that it is a chiral molecule, its structure was determined by homonuclear decoupling experiments, 1H NMR and HETCOR. The study of the intramolecular N → B coordination by dynamic NMR afforded a ΔG? value of 98.4 kJ mol-1 for compound 3. Copyright
- Mancilla, Teresa,Carrillo, Lourdes,De La Paz Reducindo
-
p. 3777 - 3785
(2008/10/09)
-
- Zwitterionic compounds and their n-halo derivatives for use in the treatment of clinical conditions
-
Zwitterionic compounds selected from: taurine (2-aminoethanesulphonic acid), 2(N-morpholino)ethanesulphonic acid (MES), N-(2-acetamido)iminodiacetic acid (ADA), piperazine-N,N'bis(2-ethanesulphonic acid (PIPES), N-(2-acetamido)-2-aminoethanesulphonic acid (ACES), N,N-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid (BES), 3-(N-morpholino)propanesulphonic (MOPS), N-N[tris(hydroxymethyl)-methyl]-2-aminoethanesulphonic acid (TES), N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid (HEPES), N-2-hydroxyethylpiperazine-N'3-propanesulphonic acid (H)EPPS), 2-(cyclohexylamino)ethanesulphonic acid (CHES) or 3-(cyclohexylamino)propanesulphonic acid (CAPS), and their N-halo derivatives can be used separately or in combination in the treatment of related clinical conditions by stimulating myeloperoxidase activity, which in turn stimulates hypochlorous acid production in vivo, which leads inter alia to enhanced leukotriene inactivation.
- -
-
-
- Use of zwitterionic compounds and their N-halo derivatives
-
Zwitterionic compounds selected from:, taurine (2-aminoethanesulphonic acid), 2(N-morpholino)ethanesulphonic acid (MES), N-(2-acetamido) iminodiacetic acid (ADA), piperazine-N,N?bis(2-ethanesulphonic acid (PIPES), N-(2-acetamido)-2-aminoethanesulphonic acid (ACES), N,N-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid (BES), 3-(N-morpholino)propanesulphonic (MOPS), N-N[tris(hydroxymethyl)-methyl]-2-aminoethanesulphonic acid (TES), N-2-hydroxyethylpiperazine-N?-2-ethanesulphonic acid (HEPES), N-2-hydroxyethylpiperazine-N?3-propanesulphonic acid ((H)EPPS), 2-(cyclohexylamino) ethanesulphonic acid (CHES) or 3-(cyclohexylamino) propanesulphonic acid (CAPS), and their N-halo derivatives can be used separately or in combination in the treatment of related clinical conditions by stimulating myeloperoxidase activity, which in turn stimulates hypochlorous acid production in vivo, which leads inter aliato enhanced leukotriene inactivation.
- -
-
-
